The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

作者：Daniel H. Mathalon, Spero Nicholas, Brian J. Roach, Tashrif Billah, Suzie Lavoie, Thomas J. Whitford, Holly Hamilton, Lauren Addamo, Andrey Anohkin, Tristán Bekinschtein, Ayşenil Belger, Kate Buccilli, John D. Cahill, Ricardo E. Carrión, Stefano Damiani, Ilvana Dzafic, Bjørn H. Ebdrup, Igor Izyurov, Johanna M. Jarcho, Raoul Jenni, Anna Jo, Sarah Kerins, Clarice Lee, Elizabeth A. Martin, Rocío Mayol-Troncoso, Margaret Niznikiewicz, Muhammad A. Parvaz, Oliver Pogarell, Juan Montalvo, Rachel A. Rabin, David R. Roalf, Jack D. Rogers, Dean F. Salisbury, Riaz Shaik, Stewart A. Shankman, Michael C. Stevens, Yi Nam Suen, Nicole C. Swann, XiaoChen Tang, Judy L. Thompson, Ivy F. Tso, Julian Wenzel, Juan Zhou, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Rolando I Castillo-Passi, Eric Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Covadonga M. Díaz‐Caneja, Lauren M. Ellman, Paolo Fusar‐Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Minah Kim, Sung‐Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesús Pérez, Diana O. Perkins, Albert R. Powers, Fred W. Sabb, Jason Schiffman, Jai Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Rachel Upthegrove, Swapna Verma, Jijun Wang, Daniel H. Wolf, Tianhong Zhang, Sylvain Bouix, Ofer Pasternak, Kang Ik K. Cho, Michael J. Coleman, Dominic Dwyer, Ángela Núñez, Zailyn Tamayo, Stephen J. Wood, René S. Kahn, John M. Kane, Patrick D. McGorry, Carrie E. Bearden, Barnaby Nelson, Scott W. Woods, Martha E. Shenton, Accelerating Medicines Partnership® Schizophrenia Program, Gregory A. Light · 发表于：Schizophrenia · 年份：2025 · DOI：10.1038/s41537-025-00622-0 · 被引用次数：8 · 研究领域：Neural dynamics and brain function、EEG and Brain-Computer Interfaces、Functional Brain Connectivity Studies

Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49-0.85; CON: mean = 0.71, range = 0.44-0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and targ...